Table 1. Clinical characteristics of the SLE study population (n = 795).
| Clinical manifestation | Total (N = 795) | Male (N = 68) | Female (N = 727) |
|---|---|---|---|
| Mean ± SD | |||
| Age | 30.71 ± 11.62 | 31.46 ± 12.52 | 30.64 ± 11.56 |
| N/evaluable cases (%) | |||
| Oral ulcer | 207/795 (26.04%) | 13/68 (19.12%) | 194/727 (26.69%) |
| Arthritis | 496/795 (62.39%) | 38/68 (55.88%) | 458/727 (63.00%) |
| Malar rash | 443/795 (55.72%) | 37/68 (54.41%) | 406/727 (55.85%) |
| Discoid rash | 150/795 (18.87%) | 16/68 (23.53%) | 134/727 (18.43%) |
| Photosensitivity | 180/795 (22.64%) | 13/68 (19.12%) | 167/727 (22.97%) |
| Pleural effusion | 154/795 (19.37%) | 12/68 (17.65%) | 142/727 (19.53%) |
| Pericardial effusion | 96/795 (12.08%) | 13/68 (19.12%) | 83/727 (11.42%) |
| Ascites | 42/795 (5.28%) | 3/68 (4.41%) | 39/727 (5.36%) |
| Nephritis | 451/795 (56.73%) | 45/68 (66.18%) | 406/727 (55.85%) |
| Neuropsychiatric manifestations | 130/795 (16.35%) | 10/68 (14.71%) | 120/727 (16.51%) |
| Leukopenia (WBC count < 3500/uL) | 451/795 (56.73%) | 41/68 (60.29%) | 410/727 (56.40%) |
| Anemia (Hb < 9 g/dL) | 247/795 (31.07%) | 11/68 (16.18%) | 236/727 (32.46%) |
| Thrombocytopenia (plat count < 105/uL) | 208/795 (26.16%) | 23/68 (33.82%) | 185/727 (25.45%) |
| Complement depressed | 615/782 (78.64%) | 53/66 (80.30%) | 562/716 (78.49%) |
| Anti-dsDNA | 590/777 (75.93%) | 52/67 (77.61%) | 538/710 (75.77%) |
| Anti-Sm | 245/646 (37.93%) | 27/60 (45.00%) | 218/586 (37.20%) |
| Anti-RNP | 279/645 (43.26%) | 24/59 (40.68%) | 255/586 (43.52%) |
| Anti-SSA | 346/535 (64.67%) | 28/45 (62.22%) | 318/490 (64.90%) |
| Anti-SSB | 139/535 (25.98%) | 8/45 (17.78%) | 131/490 (26.73%) |
| Anti-cardiolipin IgG | 178/628 (28.34%) | 12/50 (24.00%) | 166/578 (28.72%) |
| Anti-cardiolipin IgM | 52/577 (9.01%) | 4/47 (8.51%) | 48/530 (9.06%) |